HAGA.BIO, the spatial transcriptomics company, has closed a $2.3M Seed funding round. The investment marks a significant milestone for the firm, which is focused on advancing high-sensitivity in situ RNA detection.
HAGA Bioscience's core technology is designed to enable scalable RNA biomarker validation across large cohorts. By offering single nucleotide resolution, the company aims to bridge the critical gap between discovery and validation in biological research, ensuring that its insights are focused precisely where they truly matter.















